a strong trendp = 0.06
None of these studies were powered to observe mortality differences; however, the CHAMPION trial showed a strong trend towards survival benefit in HF and reduced ejection fraction (HFrEF) patients monitored with the CardioMEMS system ( p = 0.06) [ 40 ].